



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

-

Application Number

10/554185 ✓

Filing Date

October 21, 2005

First Named Inventor

Mark T. Bilodeau

Art Unit

To be determined

Examiner Name

To be determined

Attorney Docket Number

21377YP

## ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment/Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/  
Incomplete Application

☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

Remarks

- 16 references attached

☐ After Allowance Communication  
to Technology Center (TC)

☐ Appeal Communication to Board  
of Appeals and Interferences

☐ Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☐ Other Enclosure(s) (please  
Identify below):

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name

Matthew A. Leff

Registration No. (Attorney/Agent)

50,149

Signature

*Matthew A. Leff*

Date

2/15/2006

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: 2/15/2006

Typed or printed  
name


Stephanie Ricardo

Signature

*Stephanie Ricardo*

Date

2/15/2006



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mark T. Bilodeau, et al.

Serial No. 10/554,185

Filed: October 21, 2005

For: INHIBITORS OF AKT ACTIVITY

Art Unit: To be determinedExaminer: To be determined

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

**MERCK & CO., INC.**By Stephanie Richards Date 2-15-06

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


| RELATED APPLICATION |             |            |
|---------------------|-------------|------------|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Matthew A. Leff

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 50,149

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1404

Date: February 15, 2006

**COMPLETE IF KNOWN**

### STATEMENT BY APPLICANT

(use as many sheets as necessary)

1

of

3

Application Number

10/554.185

**Filing Date**

October 21, 2005

**First Named Inventor**

Mark T. Bilodeau

### Group Art Unit

To be determined

Examiner Name

To be determined

Attorney Docket Number

21377YP

[illegible]

| FOREIGN PATENT DOCUMENTS |          |                         |                |                         |   |   |
|--------------------------|----------|-------------------------|----------------|-------------------------|---|---|
| Examiner Initials*       | Cite No. | Foreign Patent Document |                |                         | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY |
|                          |          | Office                  | Number         | Kind Code<br>(if known) |   |   |
|                          |          | PCT                     | WO 97/08167 ✓  |                         | Smithkline Beecham Plc                          | 03/06/1997  |
|                          |          | PCT                     | WO 96/11929 ✓  |                         | Smithkline Beecham Plc.                         | 04/25/1996  |
|                          |          | PCT                     | WO 01/66525 ✓  |                         | Astrazeneca Ab.                                 | 09/13/2001  |
|                          |          | PCT                     | WO 97/49704 ✓  |                         | Janssen Pharmaceutica Nv.                       | 12/31/1997  |
|                          |          | PCT                     | WO 97/22360 ✓  |                         | Medical Research Council                        | 06/26/1997  |
|                          |          | PCT                     | WO 01/91754 ✓  |                         | Peptor Ltd.                                     | 12/06/2001  |
|                          |          | PCT                     | WO 96/23769 ✓  |                         | Smithkline Beecham PLC.                         | 08/08/1996  |
|                          |          | PCT                     | WO 02/083138 ✓ |                         | Merck & Co., Inc.                               | 10/24/2002  |
|                          |          | PCT                     | WO 03/084473 ✓ |                         | Merck & Co., Inc.                               | 10/16/2003  |
|                          |          | PCT                     | WO 94/10171 ✓  |                         | Pfizer Inc.                                     | 05/11/1994  |

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box-1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

|                               |                  |
|-------------------------------|------------------|
| <b>Application Number</b>     | 10/554,185       |
| <b>Filing Date</b>            | October 21, 2005 |
| <b>First Named Inventor</b>   | Mark T. Bilodeau |
| <b>Group Art Unit</b>         | To be determined |
| <b>Examiner Name</b>          | To be determined |
| <b>Attorney Docket Number</b> | 21377YP          |

|       |   |    |   |
|-------|---|----|---|
| Sheet | 2 | of | 3 |
|-------|---|----|---|

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

|                               |                  |
|-------------------------------|------------------|
| <b>Application Number</b>     | 10/554,185       |
| <b>Filing Date</b>            | October 21, 2005 |
| <b>First Named Inventor</b>   | Mark T. Bilodeau |
| <b>Group Art Unit</b>         | To be determined |
| <b>Examiner Name</b>          | To be determined |
| <b>Attorney Docket Number</b> | 21377YP          |

Sheet 3 of 3

## NON PATENT LITERATURE DOCUMENTS

**Examiner  
Signature**

Date  
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005